Year: 2024

Mothercare plc Annual General Meeting 19 November 2024: Results Annual General Meeting At the annual general meeting held at 11.00am on 19 November 2024, the resolutions before the meeting were passed. The following proxy votes had been received by the Company in respect of the resolutions: Resolutions 11 to 13 were Special Resolutions.  Resolution Votes For % Votes Against %Total votes cast (including discretionary) % ISC Votes withheld*1 To receive the annual accounts, directors’ report, strategic report, directors’ remuneration report and auditor’s report 429,307,140 99.99 63,312 0.01 429,370,452 76.15 15,9932 To approve the directors’ remuneration report 429,227,087 99.97 134,654 0.03 429,361,741 76.15 24,7043 To re-elect Clive Whiley as a director 429,253,933 99.97 108,706 0.03 429,362,639 76.15 23,8064 To re-elect...

BELTSVILLE, Md., Nov. 19, 2024 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced the presentation of preclinical data demonstrating that treatment with NC605, a novel anti-Siglec-15 (S15) antibody, resulted in enhanced generation of quality bone with better mechanical properties, in an oral presentation at the Osteogenesis Imperfecta Federation Europe virtual Investigator Meeting on November 15th, 2024. These results demonstrate that NC605 is a highly effective treatment for Osteogenesis Imperfecta (OI), also known as brittle bone disease in a well-established model of disease. OI is a rare disorder that results in high bone turnover, abnormal bone formation, bone...

CORAL GABLES, Fla., Nov. 19, 2024 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Richard J. Daly, President and CEO of Catalyst, along with other members of Catalyst’s management team, will participate in the upcoming investor conferences detailed below. Piper Sandler 36th Annual Healthcare ConferenceDate: Tuesday, December 3, 2024Presentation: 2:00 PM ETWebcast Link Citi’s 2024 Global Healthcare Conference Date: Wednesday, December 4, 2024Presentation: 1:00 PM ETWebcast Link The webcasts will be available under the Investors section on the Company’s...

Ness Ziona, Israel, Nov. 19, 2024 (GLOBE NEWSWIRE) — Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX) (“Foresight” or the “Company”), an innovator in automotive vision systems, announced that its stereoscopic 3D perception systems would likely comply with the strategic initiative of the impending Trump administration’s recent publicly stated commitment to establish a federal framework for fully self-driving vehicles and make it a top priority for the Department of Transportation. We believe that the Company’s existing 3D perception systems, leveraging a unique combination of visible-light and thermal long-wave infrared stereoscopic cameras, offer superior detection capabilities, making it well-suited for integration as the primary sensor suite in autonomous vehicles. By developing advanced vision technologies that...

MELBOURNE, Australia and SAN FRANCISCO, Nov. 19, 2024 (GLOBE NEWSWIRE) — Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), has announced the appointment of Abby Macnish Niven as Alterity’s Company Secretary following her appointment as Chief Financial Officer of Alterity. Ms Macnish Niven assumes the role of Company Secretary from Mr Phillip Hains effective on 18 November 2024. The Board and Management of Alterity thank Phillip for his valuable contributions over the past several years and appreciate the foundation he helped establish. Ms Macnish Niven was appointed as CFO on 30 September 2024 and has extensive experience in private wealth management with groups including ANZ, UBS and Ord Minett. Ms Macnish Niven consults to a range of listed and unlisted companies in governance, finance and corporate...

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Court’s approval allows transaction with Aditxt to proceed, subject to other closing conditions HALIFAX, Nova Scotia, Nov. 19, 2024 (GLOBE NEWSWIRE) — Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, is pleased to announce receipt of the final order of the Ontario Superior Court of Justice (Commercial List) for the plan of arrangement (the “Arrangement”) pursuant to which Aditxt, Inc. (“NASDAQ:ADTX”) (“Aditxt”), through its wholly-owned subsidiary, Adivir, Inc., will acquire all of the issued and outstanding Class A common shares of the Company (the “Transaction”). As previously announced, the...

AVTL filed draft red herring prospectus with Securities and Exchange Board of India19 November 2024, Rotterdam, the Netherlands Following the publication of the press release dated 29 October 2024 and the press release dated 9 July 2024, AVTL has now filed the draft red herring prospectus with the Securities and Exchange Board of India (‘SEBI’). The formal approval process with SEBI is expected to take several months.AVTL is the largest Indian third-party owner and operator of tank storage terminals for liquified petroleum gas and liquid products in terms of storage capacity, as of June 30, 2024 (Source: CRISIL Report). AVTL owns and operates a network of tank storage terminals having an aggregate storage capacity of approximately 1.50 million cubic meters for liquid products and 70,800 metric tons of static capacity for LPG as of June...

MALVERN, Pa., Nov. 19, 2024 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced positive preliminary efficacy and safety data from the Phase 1 dose-escalation portion of the Phase 1/2 OCU410 ArMaDa clinical trial for geographic atrophy (GA), secondary to dry age-related macular degeneration (dAMD). Key findings include: no drug-related serious adverse events, reduced lesion growth, preservation of retinal tissue, and—most importantly—there was a positive effect on the functional visual measure of low luminance visual acuity (LLVA). Currently, there are approximately three million people living with GA in the United States (U.S.) and Europe combined. Patients...